Skip to main content

RDHL 6-K

RedHill Biopharma Ltd. (RDHL)

6-K 2026-08-06 For: 2026-08-06
View Original
Added on August 06, 2026

UNITEDSTATES

SECURITIES ANDEXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of August 2026

Commission File No.: 001-35773

REDHILL BIOPHARMALTD.

(Translation of registrant’s name into English)

21 Ha'arba’a Street, Tel Aviv, 6473921,Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

RedHill Biopharma Ltd. (the “Company”) announces today the adjournment of the Annual General Meeting of Shareholders scheduled for August 6, 2026, due to a lack of required legal quorum.

In accordance with the Company’s Amended and Restated Articles of Association, the Annual General Meeting of Shareholders will reconvene on August 7, 2026, at 3:00 p.m. Israel time at the Company’s office.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

REDHILL BIOPHARMA LTD.
(the “Registrant”)
Date: August 6, 2026 By: /s/ Dror Ben-Asher
Name: Dror Ben-Asher
Title: Chief Executive Officer